1.
The Study Of The Changes Of Plasm Fibrinolysis Activity In Mongolian Patients With Coronary Heart Disease
蒙古族冠心病患者血浆纤溶活性的研究
2.
STUDY ON PLASMA FIBRINOLYTIC ACTIVITY CHANGES IN CORONARY HEART DISEASE PATIENTS WITH BLOOD STASIS SYNDROME AND ITS CORRELATION WITH LIPID LEVEL
冠心病血瘀证血浆纤溶活性改变及其与血脂水平的相关性研究
3.
Study of the Influence of CBA on the Activity of Fibrinolytic System and its Nursing
球囊血管成形术对患者血浆纤溶活性影响的研究及护理
4.
Study of the Relativity between Thrombin-activatable Fibrinolysis Inhibtor and Stroke
血浆凝血酶激活的纤溶抑制物与脑卒中的相关性研究
5.
The Relationship between Thrombin-Activatable Fibrinolysis Inhibitor and Risk of Stroke
血浆凝血酶激活的纤溶抑制物与脑卒中的相关性
6.
Plasma Concentrations Changes and Significance of Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in Chronic Glomerulonephritis and the Intervenient Research on Them;
慢性肾小球肾炎血浆纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂的变化与干预研究
7.
Thrombin is an enzyme that catalyzes the conversion of the soluble plasma protein fibrinogen to the insoluble protein fibrin.
凝血酶能催化可溶性血浆纤维蛋白转化为不溶性的纤维蛋白。
8.
Detection and clinical significance of plasma urokinase-type plasminogen activator and its soluble receptor in multiple myeloma patients;
多发性骨髓瘤患者血浆尿激酶型纤溶酶原激活物及其可溶性受体的检测
9.
Activity of plasma tissue plasminogen activator and plasminogen activator inhibitor in patients with hypertensive disorder complicating pregnancy
妊娠期高血压疾病患者血浆组织型纤溶酶原激活物及其抑制物的活性变化
10.
an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents.
血浆中血纤维蛋白溶酶不活跃的前体，能被有机溶剂转化成血纤维蛋白溶酶。
11.
Relationship between Thrombin Activated Fibrinolysis Inhibitor in Plasma and Vascular Complication in Type 2 Diabetes;
血浆凝血酶激活的纤溶抑制物与2型糖尿病血管并发症的关系
12.
Correlativity between blood-stasis syndrome in cardiopathy and activity of f ibrinolytic system
心病血瘀证与纤溶系统活性的相关性
13.
The inactive precursor to plasmin that is found in body fluids and blood plasma.
血纤维蛋白溶酶原血纤维蛋白溶酶不活跃的前体，常发现于体液和血浆中
14.
The clinical study of plasma thrombin activatable fibrinolysis inhibitor in the patients with stroke
脑卒中患者血浆凝血酶激活的纤溶抑制物的临床研究
15.
Relation between TNF-α in Adipose Tissue and Plasminogen Activator Inhibitor-1 in Plasma;
脂肪组织中肿瘤坏死因子-α与血浆纤溶酶原激活抑制物-1相关性的研究
16.
Expression of TNF-α protein in the omental and subcutaneous adipose tissue in obesity
肥胖者网膜脂肪肿瘤坏死因子-α的表达与血浆纤溶酶原激活抑制物-1的相关性分析
17.
Study on tissue plasminogen activator change in recurrence of stroke patients
血纤溶活性变化对缺血性脑梗死复发的影响
18.
Level changing and significance of serum lysophosphatidic acid and fibrinogen in the patients with ischemic cerebrovascular disease
缺血性脑血管病患者血浆溶血磷脂酸与血浆纤维蛋白原水平变化与意义